ATE355074T1 - Hybrid aus interferon-alpha und immunglobulin fc- fragment verbunden durch ein nicht immunogenes peptid - Google Patents

Hybrid aus interferon-alpha und immunglobulin fc- fragment verbunden durch ein nicht immunogenes peptid

Info

Publication number
ATE355074T1
ATE355074T1 AT96945126T AT96945126T ATE355074T1 AT E355074 T1 ATE355074 T1 AT E355074T1 AT 96945126 T AT96945126 T AT 96945126T AT 96945126 T AT96945126 T AT 96945126T AT E355074 T1 ATE355074 T1 AT E355074T1
Authority
AT
Austria
Prior art keywords
hybrid
immunoglobulin
gly
interferon alpha
immunogenic peptide
Prior art date
Application number
AT96945126T
Other languages
English (en)
Inventor
Tse Wen Chang
Liming Yu
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Application granted granted Critical
Publication of ATE355074T1 publication Critical patent/ATE355074T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96945126T 1995-12-28 1996-12-13 Hybrid aus interferon-alpha und immunglobulin fc- fragment verbunden durch ein nicht immunogenes peptid ATE355074T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57921195A 1995-12-28 1995-12-28
US08/719,331 US5723125A (en) 1995-12-28 1996-09-25 Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide

Publications (1)

Publication Number Publication Date
ATE355074T1 true ATE355074T1 (de) 2006-03-15

Family

ID=27077703

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96945126T ATE355074T1 (de) 1995-12-28 1996-12-13 Hybrid aus interferon-alpha und immunglobulin fc- fragment verbunden durch ein nicht immunogenes peptid

Country Status (11)

Country Link
US (2) US5723125A (de)
EP (1) EP0888122B1 (de)
JP (1) JP3507507B2 (de)
CN (1) CN1187086C (de)
AT (1) ATE355074T1 (de)
AU (1) AU701579B2 (de)
CA (1) CA2239522A1 (de)
DE (1) DE69636938T2 (de)
ID (1) ID16083A (de)
MY (1) MY116588A (de)
WO (1) WO1997024137A1 (de)

Families Citing this family (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
US6114110A (en) * 1996-01-16 2000-09-05 University Of Michigan Isolation and propagation of a human herpesvirus derived from AIDS-associated Kaposi's sarcoma cells
US20050033033A1 (en) * 1998-05-04 2005-02-10 Heinz Kohler Trans-membrane-antibody induced inhibition of apoptosis
US20030103984A1 (en) * 1998-05-04 2003-06-05 Heinz Kohler Fusion proteins of biologically active peptides and antibodies
US20040185039A1 (en) * 2002-08-30 2004-09-23 Heinz Kohler Therapeutic applications of noncovalent dimerizing antibodies
US7569674B2 (en) * 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
EP1489100B1 (de) 1997-12-08 2016-06-15 Merck Patent GmbH Heterodimäre Fusionsproteine zur Verwendung für gezielte Immuntherapie und allgemeine Immunerregung
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
RU2229305C2 (ru) * 1998-04-15 2004-05-27 Лексиген Фармасьютикэлс Корпорейшн Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
US20090208418A1 (en) * 2005-04-29 2009-08-20 Innexus Biotechnology Internaltional Ltd. Superantibody synthesis and use in detection, prevention and treatment of disease
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
SI1121382T1 (sl) * 1998-10-16 2007-02-28 Biogen Idec Inc Fuzijski proteini interferona-beta in uporabe
DK1656952T3 (da) 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
ATE369384T1 (de) * 1999-05-19 2007-08-15 Emd Lexigen Res Ct Corp Expression und export von interferon-alpha proteinen als fc fusionsproteine
CA2378519C (en) 1999-07-07 2011-01-25 Zymogenetics, Inc. Human cytokine receptor
ATE407697T1 (de) * 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
EP1228214A2 (de) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietinformen mit verbesserten eigenschaften
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001053480A1 (en) * 2000-01-24 2001-07-26 Sangamo Biosciences, Inc. Nucleic acid binding polypeptides characterized by flexible linkers connected nucleic acid binding modules
HUP0204475A2 (en) * 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
DE60129695T2 (de) * 2000-06-29 2008-06-05 Merck Patent Gmbh Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
EP1334128A2 (de) * 2000-11-02 2003-08-13 Maxygen Aps Neue multimere interferon-beta-polypeptide
MXPA03004840A (es) * 2000-12-01 2008-10-08 Verenium Corp Enzimas que tienen actividad de deshalogenasa y metodos.
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7141392B2 (en) * 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
JP2004532624A (ja) 2001-03-02 2004-10-28 ザイモジェネティクス，インコーポレイティド マウスサイトカイン受容体
WO2002098370A2 (en) * 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
CN1191271C (zh) * 2001-03-21 2005-03-02 中国科学院上海生物化学研究所 干扰素－胸腺肽融合蛋白及其制法
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
US20020193569A1 (en) * 2001-06-04 2002-12-19 Idec Pharmaceuticals Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1409982A4 (de) * 2001-06-14 2006-05-24 Anadys Pharmaceuticals Inc Verfahren zum screening auf liganden von zielmolekülen
DK1402015T3 (da) * 2001-06-22 2011-12-05 Hoffmann La Roche Opløseligt kompleks omfattende et retroviralt overfladeglycoprotein og FkpA eller SlyD
US7094757B2 (en) * 2001-06-22 2006-08-22 Roche Diagnostics Corporation Complexes comprising a prion protein and a peptidyl prolyl isomerase chaperone, and method for producing and using them
US6962982B2 (en) * 2001-06-22 2005-11-08 Roche Diagnostics Corporation Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them
US20030044386A1 (en) * 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
US20030104604A1 (en) * 2001-08-03 2003-06-05 Weiping Yang Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage
CN101200503B (zh) * 2001-08-10 2010-07-07 中国人民解放军军事医学科学院生物工程研究所 血清白蛋白与干扰素的融合蛋白
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CA2476887A1 (en) * 2002-02-21 2003-09-04 Wyeth Gasp1:a follistatin domain containing protein
BR0307871A (pt) * 2002-02-21 2005-04-12 Wyeth Corp Proteìnas contendo domìnio de folistatina
US20080108560A1 (en) * 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
RS20050035A (sr) * 2002-07-17 2007-06-04 Biogen Idec Ma Inc., Terapije bubrežne insuficijencije sa upotrebom interferona -beta
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
EP2192129A1 (de) * 2002-09-16 2010-06-02 Johns Hopkins University Metalloproteaseaktivierung von Myostatin sowie Verfahren zur Modulation der Myostatinaktivität
SI2301965T1 (sl) 2002-10-16 2015-07-31 Purdue Pharma L.P. Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
AR047392A1 (es) * 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
US20040223966A1 (en) * 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
WO2004074486A2 (en) * 2003-02-18 2004-09-02 Merck Patent Gmbh Fusion proteins of interferon alpha muteins with improved properties
US20070026014A1 (en) * 2003-04-17 2007-02-01 Ares Trading S.A. Interferon beta in severe acute respiratory syndrome (sars)
CN1535724B (zh) * 2003-04-23 2012-09-05 北京金迪克生物技术研究所 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途
CA2522690A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US20070161087A1 (en) * 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
BRPI0410927A (pt) 2003-06-02 2006-06-27 Wyeth Corp métodos terapêuticos e profiláticos para distúrbios neuromusculares
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
CA2551915C (en) * 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
PL1706428T3 (pl) 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
EP2327724A3 (de) 2004-02-02 2011-07-27 Ambrx, Inc. Modifizierte humane Wachstumshormon-Polypeptide und deren Verwendungen
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
AU2005272646A1 (en) * 2004-08-12 2006-02-23 Wyeth Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors
WO2006063055A2 (en) * 2004-12-06 2006-06-15 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
CN101072793B (zh) * 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP2192132A3 (de) 2005-02-08 2010-08-18 ZymoGenetics, Inc. Anti-il-20-, Anti-il-22- und Anti-il-22ra-Antikörper und Bindungspartner sowie Verwendungsverfahren bei Entzündungen
AU2006232914A1 (en) * 2005-03-23 2006-10-12 Wyeth Detection of an immune response to GDF-8 modulating agents
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP3214095B1 (de) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulation von immunsystemreaktionen
MX2007014889A (es) * 2005-05-26 2008-02-19 Schering Corp Fusion de interferon-inmunoglobulina g.
UA97628C2 (ru) 2005-08-16 2012-03-12 Ханми Холдингз Ко., Лтд. Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе
JP2009507003A (ja) 2005-09-01 2009-02-19 アレス トレーディング ソシエテ アノニム 視神経炎の治療
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
BRPI0620648B1 (pt) * 2005-12-30 2022-12-20 Merck Patent Gesellschaft Mit Beschrãnkter Haftung Variante de il-12 p40, proteínas il-12, il-23 e de fusão, composição farmacêutica e uso da mesma
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
EP2027291A2 (de) 2006-04-27 2009-02-25 Pikamab, Inc. Verfahren und zusammensetzungen für antikörpertherapie
AU2007253254B2 (en) 2006-05-24 2013-01-17 Merck Serono Sa Cladribine regimen for treating multiple sclerosis
AU2007275294A1 (en) * 2006-07-18 2008-01-24 Centocor, Inc. Human GLP-1 mimetibodies, compositions, methods and uses
ES2439994T3 (es) 2006-08-28 2014-01-27 Kyowa Hakko Kirin Co., Ltd. Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
WO2008057529A2 (en) * 2006-11-06 2008-05-15 Coley Pharmaceutical Group, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
WO2009012600A1 (en) * 2007-07-26 2009-01-29 Novagen Holding Corporation Fusion proteins
ES2536772T3 (es) * 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
KR101662622B1 (ko) 2007-10-04 2016-10-05 지모제넥틱스, 인코포레이티드 Ｂ7 패밀리 구성원 ｚＢ7Ｈ6 및 관련된 조성물 및 방법
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR101700711B1 (ko) 2007-11-21 2017-01-31 로스킬드 유니베르시테트 얼음-결합 활성을 포함하는 폴리펩티드
CN101952309A (zh) * 2007-12-21 2011-01-19 Ifxa有限公司 蛋白酶抑制剂
AU2009207645B2 (en) * 2008-01-25 2014-11-13 Aarhus Universitet Selective exosite inhibition of PAPP-A activity against IGFBP-4
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
UA101670C2 (ru) 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
EP2633864A1 (de) 2008-07-25 2013-09-04 The Regents of the University of Colorado Clip-Hemmer und Verfahren zur Modulation der Immunfunktion
EP2421896A1 (de) * 2009-04-22 2012-02-29 Merck Patent GmbH Antikörperfusionsproteine mit modifizierten fcrn-bindungsstellen
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
ES2666152T3 (es) 2009-08-13 2018-05-03 The Johns Hopkins University Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
PL2464664T3 (pl) * 2009-08-13 2016-02-29 Crucell Holland Bv Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
CN107412737A (zh) * 2010-01-19 2017-12-01 韩美科学株式会社 长效g‑csf缀合物的液体制剂
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
BR112012024565B1 (pt) 2010-03-26 2022-02-08 Trustees Of Dartmouth College Proteína de fusão vista imunossupressora multimérica isolada ou recombinante e composição
US20110243943A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
US8426186B2 (en) 2010-04-16 2013-04-23 Centocor Ortho Biotech Inc. Engineered potato virus A nuclear inclusion protein
SG10201505217WA (en) * 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
PH12012502244A1 (en) 2010-07-09 2016-09-30 Crucell Holland Bv Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
CN102585013B (zh) * 2011-01-07 2014-04-23 中国人民解放军军事医学科学院生物工程研究所 一种含有ω干扰素的融合蛋白及制备方法
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
CN102212139A (zh) * 2011-03-29 2011-10-12 中国人民解放军第二军医大学 森林脑炎病毒包膜E蛋白与人抗体Fc段融合蛋白及其用途
EP2742064B1 (de) * 2011-08-09 2016-07-27 UAB Profarma Derivate aus rekombinanten proteinen, homo-multimere des granulozyten-kolonie-stimulierenden faktors und verfahren zu ihrer herstellung
KR102323287B1 (ko) 2011-10-05 2021-11-05 원드 매터리얼 인코포레이티드 리튬 이온 배터리용 실리콘 나노구조체 활물질, 및 그에 관련된 공정, 조성물, 구성요소 및 디바이스
SG10201603411WA (en) 2011-10-28 2016-07-28 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN104039830A (zh) 2011-11-04 2014-09-10 诺华股份有限公司 低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
CN105001340A (zh) * 2012-01-19 2015-10-28 施怀哲维克有限公司 动物融合重组型干扰素
TWI492952B (zh) * 2012-01-20 2015-07-21 Sbc Virbac Ltd 動物融合重組型干擾素
WO2013162050A1 (ja) 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ ラクトフェリン融合タンパク質及びその製造方法
CN103044554B (zh) * 2012-05-14 2014-08-27 旭华（上海）生物研发中心有限公司 重组二聚化人尿胰蛋白酶抑制剂、其制备方法及其应用
US9731029B2 (en) 2012-05-21 2017-08-15 Massachusetts Institute Of Technology Protein retrosplicing enabled by a double ligation reaction
DK3421486T5 (da) * 2012-06-22 2024-09-16 The Trustees Of Darthmouth College Nye Vista-IG-konstruktioner og anvendelse af Vista-IG til behandling af autoimmune, allergiske og inflammatoriske lidelser
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN116574185A (zh) 2012-07-25 2023-08-11 塞尔德克斯医疗公司 抗kit抗体及其用途
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
WO2014059028A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
US9803021B2 (en) 2012-12-07 2017-10-31 The Regents Of The University Of California CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
WO2014107566A1 (en) 2013-01-04 2014-07-10 Massachusetts Institute Of Technology Surface binding of nanoparticle based drug delivery to tissue
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
SG11201509982UA (de) 2013-06-06 2016-04-28 Igenica Biotherapeutics Inc
WO2014202089A2 (en) 2013-06-18 2014-12-24 Roskilde Universitet Variants of anti-freeze polypeptides
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
PT3097122T (pt) 2014-01-24 2020-07-21 Ngm Biopharmaceuticals Inc Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9738702B2 (en) 2014-03-14 2017-08-22 Janssen Biotech, Inc. Antibodies with improved half-life in ferrets
WO2015161832A1 (zh) * 2014-04-25 2015-10-29 辅仁药业集团有限公司 长效重组人干扰素α2b-Fc融合蛋白
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
EP3142700B1 (de) 2014-05-16 2021-03-03 Medimmune, LLC Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
DK3154583T3 (da) 2014-06-04 2021-03-22 Biontech Res And Development Inc Humane monoklonale antistoffer mod gangliosid gd2
MX389695B (es) 2014-06-11 2025-03-20 Kathy A Green Uso de agonistas y antagonistas vista para suprimir o aumentar la inmunidad humoral.
WO2016036916A1 (en) 2014-09-03 2016-03-10 Bioatla, Llc Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
PL3333191T3 (pl) 2014-12-11 2021-05-04 Pierre Fabre Médicament Przeciwciała przeciwko c10orf54 i ich zastosowania
AU2016222830B2 (en) 2015-02-24 2021-02-25 Bioatla Llc Conditionally active biological proteins
MX2017011194A (es) 2015-03-03 2018-04-10 Kymab Ltd Anticuerpos, usos y métodos.
US10844122B2 (en) 2015-05-06 2020-11-24 Janssen Biotech, Inc. Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US10704035B2 (en) 2015-08-27 2020-07-07 President And Fellows Of Harvard College Compositions and methods for treatment of pain
TW201718629A (zh) * 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
WO2017078839A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
CN109789201B (zh) 2016-04-15 2023-06-16 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
EP3515943A4 (de) 2016-09-19 2020-05-06 Celgene Corporation Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
CA3080406A1 (en) 2016-10-28 2018-05-03 Nrl Pharma, Inc. Lactoferrin/albumin fusion protein and production method thereof
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
EP3713582A1 (de) 2017-11-24 2020-09-30 Merck Patent GmbH Cladribin-dosierungsplan zur verwendung bei der behandlung progressiver formen von multipler sklerose
KR102767692B1 (ko) 2018-07-20 2025-02-17 피에르 파브르 메디카먼트 Vista의 수용체
SG11202102851XA (en) 2018-09-27 2021-04-29 Celgene Corp SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
WO2021021276A1 (en) * 2019-07-26 2021-02-04 Massachusetts Institute Of Technology Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
EP4188960A4 (de) 2020-08-03 2024-09-11 Janssen Biotech, Inc. Materialien und verfahren zur multidirektionalen biotransportierung in virotherapeutika
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
EP4047016A1 (de) 2021-02-19 2022-08-24 Université de Strasbourg Anti-tenascin-c(tnc)-antikörper (nanobodies) mit einer einzigen domäne und deren verwendung
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
CA3262035A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA803943B (en) * 1979-07-31 1981-06-24 Hoffmann La Roche Homogeneous fibroblast interferon and method for manufacture thereof
US4289689A (en) * 1980-03-14 1981-09-15 Hoffmann-La Roche Inc. Preparation of homogeneous human fibroblast interferon
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
NZ198445A (en) * 1980-09-25 1984-05-31 Genentech Inc Production of human fibroblast interferon by recombinant dna technology
JPS57181098A (en) * 1981-04-30 1982-11-08 Japan Found Cancer Novel recombinant dna
JPS58110600A (ja) * 1981-12-25 1983-07-01 Kyowa Hakko Kogyo Co Ltd ヒトβ型インタ−フエロン遺伝子を含む組みかえ体プラスミド
SE436275B (sv) * 1982-11-01 1984-11-26 Malmbom Rune Ingbyra Hb Anordning vid en utmed ett underlag rorlig lasthanteringsapparat, foretredesvis en lasttruck
EP0467416A1 (de) * 1983-09-01 1992-01-22 Hybritech Incorporated Antikörperzusammensetzungen von therapeutischen Mitteln mit verlängerter Serumhalbwertzeit
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
CA1339445C (en) * 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
ATE122238T1 (de) * 1987-06-10 1995-05-15 Dana Farber Cancer Inst Inc Bifunktionelle antikörperkonstruktionen und verfahren zur selektiven tötung von zellbeständen.
US4973478A (en) * 1987-07-20 1990-11-27 Allelix Biopharmaceuticals, Inc. Treating inflammation with hepatocyte stimulating factor interferon β2
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
DE3850542T2 (de) * 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
PT89484B (pt) * 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
WO1990002338A1 (en) * 1988-08-19 1990-03-08 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
CA2010321C (en) * 1989-02-21 2004-04-06 Thomas F. Tedder Lymphocyte-associated cell surface protein
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DK0745852T3 (da) * 1989-03-16 2002-10-14 Blood Res Center Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
AU648041B2 (en) * 1989-08-23 1994-04-14 General Hospital Corporation, The Non-human primate CD4 polypeptides, fusions thereof, DNA encoding, and uses thereof
DK0493418T3 (da) * 1989-09-20 1997-11-03 Abbott Lab Fremgangsmåde til fremstilling af fusionsproteiner
WO1991016353A1 (en) * 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses

Also Published As

Publication number Publication date
EP0888122A4 (de) 2002-01-09
WO1997024137A1 (en) 1997-07-10
US5908626A (en) 1999-06-01
US5723125A (en) 1998-03-03
JP3507507B2 (ja) 2004-03-15
DE69636938T2 (de) 2007-11-08
AU1356797A (en) 1997-07-28
HK1017261A1 (en) 1999-11-19
EP0888122A1 (de) 1999-01-07
CN1187086C (zh) 2005-02-02
ID16083A (id) 1997-09-04
AU701579B2 (en) 1999-02-04
CN1206350A (zh) 1999-01-27
CA2239522A1 (en) 1997-07-10
MY116588A (en) 2004-02-28
JPH11505132A (ja) 1999-05-18
DE69636938D1 (de) 2007-04-12
EP0888122B1 (de) 2007-02-28

Similar Documents

Publication Publication Date Title
ATE355074T1 (de) Hybrid aus interferon-alpha und immunglobulin fc- fragment verbunden durch ein nicht immunogenes peptid
CA2142007A1 (en) Immunomodulatory peptides
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
DK0839196T3 (da) Humant CTLA-8 og anvendelser af CTLA-8-relaterede proteiner
DK35593D0 (da) Polypeptid kodet af lav-dna-sekvens
PL336295A1 (en) Modified tnfalpha molecule, dna encoding such molecule and vaccine comprising such tnfalpha molecule and such dna
EP1845108A3 (de) Monoklonale Antikörper gegen gereinigte Hüllproteine des Hepatitis-C-Virus für diagnostische und therapeutische Zwecke
CA2081028A1 (en) Cd2 binding domain of lymphocyte function associated antigen 3
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
AU2197392A (en) Hepatitis C virus from C-100-3 and env/core regions
ATE282634T1 (de) Chaperonin 10
EA200000685A1 (ru) Комплекс ifnar2/ifn
ATE256185T1 (de) T-zell-membranprotein (tirc7), davon abgeleitete peptide und antikörper und ihre verwendungen
ATE154638T1 (de) Mutanten von interleukin-3
ATE133708T1 (de) Immunogenisches peptid von echinococcus granulosis, dafür kodierende dns sowie diagnostische und therapeutische verwendungen
FR2736916B1 (fr) Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
EP0656010B8 (de) Verwendung von Peptiden welche eine Immunantwort bewirken zur Herstellung von Medikamenten zur Induzierung der Immunsuppression.
ATE254179T1 (de) Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen
DE69928947D1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
ATE315646T1 (de) Leukocyten-aktivierender faktor
DE69332583D1 (de) Maspin- ein neues serpin mit tumor unterdrückender aktivität
ITFI920071A0 (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vogeesndk
WO2000026240A3 (en) Streptococcal alpha2m-binding protein

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0888122

Country of ref document: EP

REN Ceased due to non-payment of the annual fee